Perceptive Advisors is a notable healthcare-focused investment firm; a new 5%+ passive stake signals conviction in Nurix's pipeline. Monitor for any subsequent 13D conversion or additional filings that could indicate a shift to activist intent.
Price Chart
Executive Summary
Perceptive Advisors LLC, a healthcare-focused investment firm, filed a Schedule 13G disclosing a 5.3% passive stake in Nurix Therapeutics, Inc. as of September 16, 2026. The stake of 5,536,629 shares is held through the Perceptive Life Sciences Master Fund, Ltd., with Joseph Edelman as the managing member. This is a new passive filing, not an amendment, and the investor certifies no intent to influence control.
Key Financial Metrics
Key Facts
- Perceptive Advisors LLC disclosed a 5.3% beneficial ownership stake in Nurix Therapeutics, Inc.
- Stake consists of 5,536,629 shares of common stock held by Perceptive Life Sciences Master Fund, Ltd.
- Filing is a new Schedule 13G, not an amendment, indicating passive investment intent.
- Joseph Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the shares.
- Ownership percentage based on 103,781,683 shares outstanding as of June 30, 2026.
Financial Impact
5.3% passive stake valued at approximately $5.5 million based on 5,536,629 shares (no per-share price provided in filing).
Risk Factors
- Passive 13G filing — no indication of activist intent, but Perceptive could convert to 13D if strategy changes.
- Biotech sector volatility and clinical-stage pipeline risks remain for Nurix.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001193125-26-399480 |
| Document: 0001193125-26-399480-index.html | 0001193125-26-399480 |
| Document: 0001193125-26-399480.txt | 0001193125-26-399480 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Insider Cluster | $24.42 | awaiting T+20 | — | $25.55 (+4.63%) |
Oct 14, 2026 13d ago | 144 | $24.95 | awaiting T+20 | — | $25.55 (+2.40%) |
Oct 13, 2026 14d ago | 8-K | $22.13 | awaiting T+20 | — | $25.55 (+15.45%) |
Oct 5, 2026 22d ago | Press Release | $22.88 | awaiting T+20 | — | $25.55 (+11.67%) |
Sep 23, 2026 4w ago | SC 13G | $23.65 $25.51 | ▲ +7.86% | ▲ +8.28% | $25.55 (+8.03%) |
Sep 2, 2026 7w ago | Insider Cluster | $25.32 $22.99 | ▼ −9.20% | ▼ −8.01% | $25.55 (+0.91%) |
Aug 5, 2026 11w ago | Insider Cluster | $25.22 | awaiting T+20 | — | $25.55 (+1.31%) |
Aug 5, 2026 11w ago | Insider Cluster | $25.12 | awaiting T+20 | — | $25.55 (+1.71%) |
Aug 4, 2026 11w ago | Insider Cluster | $25.12 | awaiting T+20 | — | $25.55 (+1.71%) |
Aug 3, 2026 12w ago | Insider Cluster | $24.69 | awaiting T+20 | — | $25.55 (+3.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers